RECEIVE

II. Claims 8-17, drawn to a nucleic acid, vector, host cell and method of expression

III. Claims 19-20, drawn to a method of preventing or treating a bone loss

FEB 01%

Applicants provisionally elect with traverse the invention corresponding to Group I, Claims 1-7 and 18.

Applicant acknowledge that the remaining claims 8-17 and 19-20 are withdrawn from further consideration.

## Requirements for disclosure of nucleotide sequences and/or amino acid sequences

The Examiner has indicated that the application fails to comply with the requirements of 37 CFR 1.821-1.825. Applicants submit herewith a sequence listing in paper and computer-readable form and a statement that the content of the paper and computer readable copies are the same. Applicants believe that the application is in compliance with the requirements for sequence disclosures.

## **CONCLUSION**

It is believed that Claims 1-7 and 18 are in condition for allowance and an early notice thereof is solicited.

Respectfully submitted,

Robert B. Winter

Attorney/Agent for Applicant(s)

Registration No.: 34,458 Phone: (805) 447-2425 Date: January 22, 2001

Please send all future correspondence to: U.S. Patent Operations/ RBW Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1789